Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue SUPPL.1, 2012, Pages

  Carey, Elizabeth J ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

ARTICLE; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSPLASIA; ENTERITIS; HUMAN; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHOLAGOGUES AND CHOLERETICS; COLORECTAL NEOPLASMS; HUMANS; URSODEOXYCHOLIC ACID;

EID: 84868712865     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(12)70023-2     Document Type: Article

References (38)

1. Bajor A., Gillberg P.G., Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010, 45:645-664.
2. Fracchia M., Pellegrino S., Secreto P., Pera A., Galatola G. Biliary lipid composition in idiopathic bile acid malabsorption. Gut 1998, 43:812-816.
3. Morvay K., Szentleleki K., Torok G., Pinter A., Borzsonyi M., Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats. Dis Colon Rectum 1989, 32:860-863.
4. Narisawa T., Magadia N.E., Weisburger J.H., Wynder E.L. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 1974, 53:1093-1097.
5. Zusman I., Chevion M., Kitrosski N. Effects of N'methyl-N'-nitro-N-nitrosoguanidine and deoxycholic acid on the content of free radicals in rat serum. Exp Toxicol Pathol 1992, 44:187-189.
6. Pereira M.A., Wang W., Kramer P.M., Tao L. DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon. Cancer Lett 2004, 212:145-151.
7. Nagengast F.M., Grubben M.J., van Munster I.P. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995, 31A:1067-1070.
8. Hamada K., Umemoto A., Kajikawa A., Seraj M.J., Monden Y. In vitro formation of DNA adducts with bile acids. Carcinogenesis 1994, 15:1911-1915.
9. Bernstein C., Bernstein H., Garewal H., Dinning P., Jabi R., Sampliner R.E., et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 1999, 59:2353-2357.
10. Bernstein H., Bernstein C., Payne C.M., Dvorakova K., Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005, 589:47-65.
11. Booth L.A., Gilmore I.T., Bilton R.F. Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved?. Free Radic Res 1997, 26:135-144.
12. Kulkarni M.S., Cox B.A., Yielding K.L. Requirements for induction of DNA strand breaks by lithocholic acid. Cancer Res 1982, 42:2792-2795.
13. Payne C.M., Weber C., Crowley-Skillicorn C., Dvorak K., Bernstein H., Bernstein C., et al. Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 2007, 28:215-222.
14. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
15. Poupon R. Ursodeoxycholic acid and bile acids mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36. In press.
16. Mitsuyoshi H., Nakashima T., Sumida Y., Yoh T., Nakajima Y., Ishikawa H., et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999, 263:537-542.
17. Pongracz J., Clark P., Neopt olemos J.P., Lord J.M. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 1995, 61:35-39.
18. Minami T., Tojo H., Shinomur a Y., Matsuzawa Y., Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994, 35:1593-1598.
19. Ikegami T., Matsuzaki Y., Shoda J., Kano M., Hirabayashi N., Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998, 134:129-139.
20. Rigas B., Tsioulias G.J., Allan C., Wali R.K., Brasitus T.A. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994, 83:319-323.
21. Khare S., Mustafi R., Cerda S., Yuan W., Jagadeeswaran S., Dougherty U., et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer 2008, 60:389-400.
22. Narisawa T., Fukaura Y., Terada K., Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998, 89:1009-1013.
23. Kohno H., Suzuki R., Yasui Y., Miyamoto S., Wakabayashi K., Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 2007, 13:2519-2525.
24. van Heumen B.W., Roelofs H.M., Te Morsche R.H., Marian B., Nagengast F.M., Peters W.H. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. Exp Cell Res 2012, 318:819-827.
25. Ochsenkuhn T., Marsteller I., Hay U., Diebold J., Paumgartner G., Goke B., et al. Does ursodeoxycholic acid change the proliferation of the colorectal mucosa? A randomized, placebocontrolled study. Digestion 2003, 68:209-216.
26. Alberts D.S., Martinez M.E., Hess L.M., Einspahr J.G., Green S.B., Bhattacharyya A.K., et al. Phase III trial of trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005, 97:846-853.
27. Sjoqvist U., Tribukait B., Ost A., Einarsson C., Oxelmark L., Lofberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004, 24:3121-3127.
28. Loftus E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
29. Soetikno R.M., Lin O.S., Heidenreich P.A., Young H.S., Blackstone M.O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
30. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
31. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
32. Chapman R., Fevery J., Kalloo A., Nagorney D.M., Boberg K.M., Shneider B., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
33. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
34. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
35. Wolf J.M., Rybicki L.A., Lashner B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783-788.
36. Eaton J.E., Silveira M.G., Pardi D.S., Sinakos E., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011, 106:1638-1645.
37. Lindstrom L., Boberg K.M., Wikman O., Friis-Liby I., Hultcrantz R., Prytz H., et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012, 35:451-457.
38. Serfaty L., De Leusse A., Rosmorduc O., Desaint B., Flejou J.F., Chazouilleres O., et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003, 38:203-209.